Mettler-Toledo International Inc (MTD)

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.

Ticker
MTD
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$37.14B
52-week range
$1023.05 - $1806.58

Valuation

Share price
$1737.56 (close of Nov 18, 2026)
P/E (TTM)
37.08x
Price to book
478.27x
Price to free cash flow
42.67x
Enterprise value
$39.11B
Book value per share
$3.58

Price performance

PeriodChange
1 day+1.44%
5 days-0.65%
1 month+7.11%
3 months+24.14%
6 months+61.66%
Year to date+24.63%
1 year+24.43%
3 years+65.63%
5 years+12.52%
10 years+318.71%
All time+11,581.06%

Short interest

As of
Oct 30, 2026
Short % of float
3.56%
Shares short
616.44K
Days to cover
3.43
Change since prior report
-6.27%
Source
FINRA consolidated short interest

Members of Congress who disclosed MTD trades

Julia Letlow · Robert Bresnahan · Julie Johnson

Super investors holding MTD

Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Wallace Weitz (Weitz Investment Management)

Profitability and growth

Return on invested capital
44.05%*
Return on assets
23.41%
Return on capital employed
44.44%*
Gross margin
59.37%
Net margin
21.59%
EBITDA margin
29.73%
Revenue growth
3.98%
Net income growth
0.70%
Free cash flow growth
-1.83%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
2.34%
Current ratio
1.10x
Net debt to EBITDA
1.49x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$4.03B
Cost of revenue
$1.64B
Gross profit
$2.39B
EBITDA
$1.20B
Net income
$869.19M
Earnings per share
$42.17
Research and development
$199.37M
Interest expense
$68.52M
Shares outstanding
20.61M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$4.03B$2.39B$869.19M$42.17
2024-12-31$3.87B$2.33B$863.14M$40.67
2023-12-31$3.79B$2.24B$788.78M$36.10
2022-12-31$3.92B$2.31B$872.50M$38.79
2021-12-31$3.72B$2.17B$768.99M$33.25
2020-12-31$3.09B$1.80B$602.74M$25.24
2019-12-31$3.01B$1.74B$561.11M$22.84
2018-12-31$2.94B$1.68B$512.61M$20.33
2017-12-31$2.73B$1.58B$375.97M$14.62
2016-12-31$2.51B$1.44B$384.37M$14.49

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3159.37%21.59%-44.05%*
2024-12-3160.06%22.29%-49.70%*
2023-12-3159.16%20.82%-44.86%*
2022-12-3158.88%22.26%-45.50%*
2021-12-3158.41%20.68%-41.18%*
2020-12-3158.38%19.54%213.23%37.37%*
2019-12-3157.87%18.65%133.35%33.24%*
2018-12-3157.38%17.46%86.87%31.84%*
2017-12-3157.82%13.80%68.70%26.77%*
2016-12-3157.32%15.32%88.37%31.03%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$66.89M$2.09B
2024-12-31$59.36M$1.83B
2023-12-31$69.81M$1.89B
2022-12-31$95.97M$1.91B
2021-12-31$98.56M$1.58B
2020-12-31$94.25M$1.28B
2019-12-31$207.78M$1.24B
2018-12-31$178.11M$985.02M
2017-12-31$148.69M$960.17M
2016-12-31$158.67M$875.06M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$848.65M$22.51M
2024-12-31$864.45M$19.98M
2023-12-31$860.55M$17.93M
2022-12-31$737.83M$19.66M
2021-12-31$801.25M$19.59M
2020-12-31$632.21M$18.69M
2019-12-31$506.11M$18.29M
2018-12-31$422.28M$17.58M
2017-12-31$388.90M$16.58M
2016-12-31$336.80M$15.31M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-05Sep 2026$12.11
2026-07-30Jun 2026$10.78
2026-05-07Mar 2026$8.70
2026-02-05Dec 2025$12.76
2025-11-06Sep 2025$10.62
2025-07-31Jun 2025$9.58
2025-05-01Mar 2025$7.90
2025-02-06Dec 2024$11.69

Filings and sources

Company website
mt.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Quest Diagnostics Inc (DGX) · Illumina, Inc. (ILMN) · Labcorp Holdings Inc. (LH) · Waters Corp (WAT) · Medpace Holdings, Inc. (MEDP) · IDEXX Laboratories Inc (IDXX) · Revvity, Inc. (RVTY) · IQVIA Holdings Inc. (IQV)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades